George Fromm, PhD
Chief Scientific Officer, ARC Platform
George has served as our Chief Scientific Officer, ARC Platform since January, 2023. He previously served as the Vice President of R&D. George joined Shattuck Labs in 2017 and is one of its scientific co-founders, co-leading the development of first-in-human SL-279252 and SL-172154 into clinical trials. Previously, George served as the Senior Director of Research and Development at Heat Biologics, Inc., where he directed the Discovery and Clinical based research efforts for their phase I/II trials, and co-invented a ‘next-generation’ vaccine platform that combines a cell based immunotherapy vaccine and a T cell costimulatory fusion protein in a single treatment. He has authored IND submissions, several NIH and Private Foundation Grants, and was a recipient of an NIH T32 Training Grant Fellowship. George has also authored numerous publications in leading journals, including Cell, Molecular Cell, Genes and Development, and Blood. He received his M.S. and Ph.D. from the University of Rochester, NY and conducted his post-doctoral fellowship training with the NIH branch; National Institute of Environmental Health Sciences.